Clinical TrialsThe likelihood of success for the Phase III AURORA trial is very high given the impressive Phase IIb data.
Financial HealthCartesian's balance sheet should support operations into mid-2027, including the completion of the planned Phase 3 AURORA trial of Descartes-08 in myasthenia gravis.
Regulatory DevelopmentsCartesian received a Special Protocol Assessment (SPA) agreement on the study design for the Descartes-08's Phase 3 AURORA study in MG, which helps de-risk the Phase 3 trial.